Sumitomo Mitsui DS Asset Management Company Ltd Raises Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.2% during the 4th quarter, Holdings Channel reports. The firm owned 48,945 shares of the medical research company’s stock after buying an additional 119 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in IQVIA were worth $9,618,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently modified their holdings of IQV. Sanctuary Advisors LLC acquired a new position in IQVIA in the 2nd quarter worth approximately $803,000. Czech National Bank boosted its holdings in shares of IQVIA by 1.6% in the 3rd quarter. Czech National Bank now owns 35,279 shares of the medical research company’s stock valued at $8,360,000 after acquiring an additional 559 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of IQVIA by 36.1% during the third quarter. GAMMA Investing LLC now owns 1,101 shares of the medical research company’s stock worth $261,000 after purchasing an additional 292 shares during the last quarter. Wedmont Private Capital lifted its position in IQVIA by 9.5% during the third quarter. Wedmont Private Capital now owns 2,042 shares of the medical research company’s stock valued at $460,000 after purchasing an additional 178 shares during the period. Finally, Bruce G. Allen Investments LLC boosted its holdings in IQVIA by 1,013.6% in the third quarter. Bruce G. Allen Investments LLC now owns 245 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 223 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

IQVIA stock opened at $208.13 on Friday. The company has a fifty day simple moving average of $200.53 and a 200-day simple moving average of $219.80. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market capitalization of $37.78 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 2.15 and a beta of 1.48. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.17% and a net margin of 9.17%. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.18 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director John G. Danhakl purchased 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

IQV has been the subject of several analyst reports. Robert W. Baird decreased their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. Stephens started coverage on IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. UBS Group dropped their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday. Finally, JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $252.39.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.